In summary, our findings shed light on a previously unrecognized role of the RIG-I agonist M8 as a potential therapeutic option to kill HPV+ cancer cells and provide the proof-of-concept that RIG-I triggering by M8 can be used in combination with standard chemotherapies to enhance their anticancer efficacy. The gene discussed is RIGI; the disease is cancer.